Wassen International has announced it has entered a research deal with the University of Roehampton to progress further studies on its Efamol brand.
The three-year partnership will see Wassen working with Dr Simon Dyall, Senior Lecturer and Course Convener for the MSc in Clinical Neuroscience, who, over the past three years, has completed two studies into the relationship between omega 3 fatty acid intake and mobility and cognitive function in older adults. Efamol is now working with Dr Dyall on two further studies continuing to look at the role of omega 3 fatty acids combined with other nutrients for brain health, in particular, stress and anxiety.
Dr Dyall commented: “We will be undertaking two studies in young adults. The first will be a short duration study of 12 weeks to look specifically for the first time at the effects of supplementation on those with low blood omega 3 fatty acid levels and the second will be a longer six-month study. This will not pre-screen for fatty acid status to ensure a diverse study population but will look at the responses in different circulating omega 3 fatty acid levels.”
Victoria Malcolm, Marketing Director for Wassen, added: “We are delighted with the work that has already taken place looking at mobility and cognitive function in older women and will be announcing the results of this study in June. We look forward to our continued relationship with the university to support the launch of new products in the future.”
